BACKGROUND: Preclinical and clinical data suggest synergy for gemcitabine and oxaliplatin. These agents were tested in several known cancers that also comprise the common carcinoma of unknown primary (CUP) subtypes; namely, lung and pancreaticobiliary profiles. METHODS: The study enrolled 29 patients of whom 28 patients were eligible for treatment. Gemcitabine was given at 1,000 mg/m(2) as a fixed dose rate infusion and oxaliplatin was infused at 100 mg/m(2) every 2 weeks with restaging performed after 3 cycles at 6 weeks. RESULTS: The study reported one complete response (CR) (4%), 6 patients with a partial response (PR) (25%), and 13 with stable disease (SD) (54%); and 4 patients had progressive disease (PD) (17%) on restaging. Median overall survival (OS) and progression-free survival were 12.8 months (95% confidence interval [CI] 8.5-18.5) and 3.1 months (95% CI 1.7-6), respectively. The 1-year OS was 54%. The most common grade 3 toxicities were nausea (22%), vomiting (15%), and fatigue (11%). There were no grade 4 toxicities. This study was closed early as we moved from an empiric therapy platform to a more individualized approach. CONCLUSIONS: Gemcitabine and oxaliplatin is a well-tolerated regimen in CUP with similar outcomes to previously documented CUP studies. In selected good performance status patients this combination may serve as a first-line doublet chemotherapy option for CUP patients.
BACKGROUND: Preclinical and clinical data suggest synergy for gemcitabine and oxaliplatin. These agents were tested in several known cancers that also comprise the common carcinoma of unknown primary (CUP) subtypes; namely, lung and pancreaticobiliary profiles. METHODS: The study enrolled 29 patients of whom 28 patients were eligible for treatment. Gemcitabine was given at 1,000 mg/m(2) as a fixed dose rate infusion and oxaliplatin was infused at 100 mg/m(2) every 2 weeks with restaging performed after 3 cycles at 6 weeks. RESULTS: The study reported one complete response (CR) (4%), 6 patients with a partial response (PR) (25%), and 13 with stable disease (SD) (54%); and 4 patients had progressive disease (PD) (17%) on restaging. Median overall survival (OS) and progression-free survival were 12.8 months (95% confidence interval [CI] 8.5-18.5) and 3.1 months (95% CI 1.7-6), respectively. The 1-year OS was 54%. The most common grade 3 toxicities were nausea (22%), vomiting (15%), and fatigue (11%). There were no grade 4 toxicities. This study was closed early as we moved from an empiric therapy platform to a more individualized approach. CONCLUSIONS:Gemcitabine and oxaliplatin is a well-tolerated regimen in CUP with similar outcomes to previously documented CUP studies. In selected good performance status patients this combination may serve as a first-line doublet chemotherapy option for CUP patients.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Gauri R Varadhachary; Dmitri Talantov; Martin N Raber; Christina Meng; Kenneth R Hess; Tim Jatkoe; Renato Lenzi; David R Spigel; Yixin Wang; F Anthony Greco; James L Abbruzzese; John D Hainsworth Journal: J Clin Oncol Date: 2008-09-20 Impact factor: 44.544
Authors: Gauri R Varadhachary; Yael Spector; James L Abbruzzese; Shai Rosenwald; Huamin Wang; Ranit Aharonov; Heather R Carlson; Dalia Cohen; Siddharth Karanth; Joanna Macinskas; Renato Lenzi; Ayelet Chajut; Tina B Edmonston; Martin N Raber Journal: Clin Cancer Res Date: 2011-04-29 Impact factor: 12.531
Authors: Charles H Weissman; Craig H Reynolds; Marcus A Neubauer; Sharon Pritchard; Svetlana Kobina; Lina Asmar Journal: J Thorac Oncol Date: 2011-02 Impact factor: 15.609
Authors: Bryan J Schneider; Basil El-Rayes; Jeffery H Muler; Philip A Philip; Gregory P Kalemkerian; Kent A Griffith; Mark M Zalupski Journal: Cancer Date: 2007-08-15 Impact factor: 6.860
Authors: E Briasoulis; G Fountzilas; A Bamias; M A Dimopoulos; N Xiros; G Aravantinos; E Samantas; H Kalofonos; T Makatsoris; N Mylonakis; P Papakostas; D Skarlos; I Varthalitis; N Pavlidis Journal: Cancer Chemother Pharmacol Date: 2007-09-28 Impact factor: 3.333
Authors: Sandrine Faivre; Denise Chan; Richard Salinas; Barbara Woynarowska; Jan M Woynarowski Journal: Biochem Pharmacol Date: 2003-07-15 Impact factor: 5.858
Authors: T André; J M Reyes-Vidal; L Fartoux; P Ross; M Leslie; O Rosmorduc; M R Clemens; C Louvet; N Perez; F Mehmud; W Scheithauer Journal: Br J Cancer Date: 2008-09-16 Impact factor: 7.640